Allogene Therapeutics (ALLO) Loses -31.94% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Allogene Therapeutics (ALLO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Allogene's Q1 Earnings In Line With Estimates, Sales Nil
ALLO's first-quarter earnings match estimates. Devoid of marketed products, the company records nil sales in the quarter.
Allogene Therapeutics, Inc. (ALLO) Q1 2025 Earnings Call Transcript
Allogene Therapeutics, Inc. (NASDAQ:ALLO ) Q1 2025 Earnings Conference Call May 13, 2025 5:00 PM ET Company Participants Christine Cassiano - EVP, Chief Corporate Affairs & Brand Strategy Officer David Chang - Co-Founder, President, CEO & Director Zachary Roberts - EVP, Research & Development & CMO Geoff Parker - EVP & CFO Conference Call Participants Michael Yee - Jefferies Tyler Van Buren - TD Cowen Biren Amin - Piper Sandler Brian Chang - JPMorgan Matthew Biegler - Oppenheimer Samantha Semenkow - Citi John Newman - Canaccord Genuity William Pickering - Bernstein Operator Hello. Thank you for standing by, and welcome to Allogene Therapeutics First Quarter and 2025 Conference Call.
Allogene's Q4 Loss Narrower Than Expected, Revenues Nil
ALLO's fourth-quarter earnings beat estimates. Devoid of marketed products, the company records no sales in the quarter.
Allogene Therapeutics, Inc. (ALLO) Q4 2024 Earnings Call Transcript
Allogene Therapeutics, Inc. (NASDAQ:ALLO ) Q4 2024 Earnings Conference Call March 13, 2025 5:00 PM ET Company Participants Christine Cassiano - EVP, Chief Corporate Affairs & Brand Strategy Officer David Chang - Co-Founder, President, CEO & Director Zachary Roberts - EVP, Research & Development & CMO Geoff Parker - EVP & CFO Conference Call Participants Tyler Van Buren - TD Cowen Michael Yee - Jefferies Brian Cheng - JPMorgan Sami Corwin - William Blair Jack Allen - Baird Biren Amin - Piper Sandler John Newman - Canaccord Genuity Asthika Goonewardene - Truist Matthew Biegler - Oppenheimer Shelby Tucker - RBC Capital Markets Samantha Semenkow - Citi Carolina Ibanez-Ventoso - Stifel Laura Prendergast - Raymond James Operator Hello. Thank you for standing by, and welcome to Allogene Therapeutics Fourth Quarter and Full Year 2024 Conference Call.
Allogene: Assessing The Pipeline, Competitive Landscape, And Opportunities
Allogene Therapeutics is developing allogeneic CAR-T cells for cancer and autoimmune diseases, offering off-the-shelf therapies that reduce costs and treatment times. Cema-cel, Allogene's leading product, shows promise in first-line treatment of large B-cell malignancies, with significant revenue potential and positive clinical trial results. Allogene's financial health is stable, with a cash runway until Q1, 2026, and the company is rated a "Buy" for long-term, high-risk-tolerant investors.
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025
Here we present three biotech stocks, ALLO, DAWN and IMCR, which took a beating in 2024 but have upside potential for 2025.
Allogene Therapeutics (ALLO) Upgraded to Buy: What Does It Mean for the Stock?
Allogene Therapeutics (ALLO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying
We present three small biotech stocks, which according to Wall Street analysts, have upside potential for 2025.
Allogene Therapeutics Loses 23% Year to Date: How to Play the Stock?
The dip in ALLO's share price can be attributed to strategic changes in its pipeline, which delayed bringing its lead drug to market by at least two years.
Allogene Therapeutics (ALLO) Upgraded to Buy: Here's Why
Allogene Therapeutics (ALLO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Allogene's Q3 Loss Narrower Than Expected, Sales Nil
ALLO's third-quarter earnings beat estimates. Devoid of marketed products, management records no sales in the quarter.
